Section I: Introduction 1. Parkinson's Disease Pathogenesis: From Molecular Insights to Novel Therapies 2. Cultural and Regional Considerations in Parkinson's Pharmacotherapy 3. The Tango of Parkinson's Treatment: The Dance of Balance and Harmony 4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson's Disease 5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson's Disease: A Systematic Review Section II: L-DOPA and DOPAMINERGIC AGENTS 6. Dopaminergic Treatments for Parkinson's Disease: Seeing the Unseen 7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones 8.
D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents 9. Non-Dopaminergic Therapies Section III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE 10. Management of Motor Symptoms 11. Non-Motor Symptoms and Their Pharmacological Management 12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease 13. Clinical Case Studies and Practical Applications 14. Epigenetic Modulators: Emerging Players in Parkinson's Pharmacotherapy Section IV: FUTURE THERAPEUTIC POSSIBILITIES 15. Emergent Therapeutic Agents in the Treatment of Parkinson's Disease 16.
Future Directions in Parkinson's Disease Pharmacotherapy 17. Pioneering The Next Generation Of Therapies 18. Genetic Therapies for Parkinson's Disease: The Dawn of Precision Medicine 19. The Gastrointestinal Microbiota and Parkinson's Disease: What is known and what is still unknown. 20. Artificial Intelligence and Machine Learning in Parkinson's Drug Development 21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson's Disease Section V: PHARMACOTHERAPY: HOPES AND HYPES 22. Neuroprotective Therapies in Parkinson's Disease 23.
Polypharmacy and combination therapies in Parkinson's Disease 24. Repurposing Existing Drugs for Parkinson's Disease Management 25. Personalized Medicine andin Parkinson's Disease: Bridging Research and Practice 26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy 27. Natural products in the management of Parkinson's disease in animal models Section VI: COGNITIVE NEHANCERS AND PD PHARMACOTHERAPY 28. Cognitive Enhancers in Parkinson's Disease 29. Emerging Targets for Cognitive Enhancement 30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy 31.
Personalized Medicine for Cognitive Impairments in PD 32. Ethical and Practical Challenges with Cognitive Enhancers 33. Unani Pharmacotherapy in the Management of Parkinson's disease: A Therapeutic Approach 34. Music therapy and its synergy with pharmacotherapy in Parkinson's Disease 35. Summary and Conclusion.